3 not yet recruiting, 2 active not recruiting, 2 recruiting, 1 unknown. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Not yet recruiting 3, Active not recruiting 2, Recruiting 2, Unknown 1 |
| Phase 2 | 5 | Not yet recruiting 3, Active not recruiting 1, Recruiting 1 |
Follow PD-1 Inhibitor: new trials by email Literature Review of PD-1 Inhibitor trials Research Report on PD-1 Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study Low-dose Radiotherapy, Pucotenlimab, AG regimen - Pancreatic Cancer, PD-L1 | Phase 1 / Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 10 | 2025-09-30 | 2026-01-26 |
| Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases. - Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 30 | 2025-09-01 | 2025-08-21 |
| Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders. PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders. - EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 50 | 2025-09-01 | 2025-08-21 |
| Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta) - Leptomeningeal Metastasis, Pemetrexed | Phase 1 / Phase 2 | Active not recruiting | Guangzhou Medical University | 39 | 2025-03-17 | 2026-10-13 |
| Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer fruquintinib + tislelizumab + FOLFOX - Gastric (Stomach) Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 44 | 2025-03-01 | 2025-03-12 |
| Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer Whole Brain Low Dose Radiotherapy, Pemetrexed, Sintilimab - NSCLC, Low Dose Radiotherapy | Phase 1 | Recruiting | Sichuan University | 10 | 2024-04-25 | 2026-05-08 |
| G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma PEG-rhG-CSF - Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor | Phase 1 | Unknown | Sun Yat-sen University | 25 | 2022-01-24 | 2022-02-03 |
| Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. Low Dose Radiotherapy, stereotactic body radiation therapy, PD-1 Inhibitors - NSCLC, Low Dose Radiotherapy | Phase 1 | Active not recruiting | Sichuan University | 9 | 2021-12-15 | 2026-05-11 |
Meningeal Carcinomatosis (2) · Epstein-Barr Virus Infections (1) · Infections (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (4) · Central Nervous System Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Meningeal Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · DNA Virus Infections (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Herpesviridae Infections (1) · Pancreatic Diseases (1)
Radiotherapy (3) · Immune Checkpoint Inhibitors (2) · Lenalidomide (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2) · Pemetrexed (2) · Tenofovir (2) · Drug Therapy (1) · Folfox protocol (1) · HMPL-013 (1) · Radiosurgery (1) · pegylated granulocyte colony-stimulating factor (1) · sintilimab (1) · tislelizumab (1)
Sichuan University (2) · The Affiliated Hospital of Xuzhou Medical University (2) · Guangzhou Medical University (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Sun Yat-sen University (1) · Zhejiang Provincial People's Hospital (1)
China (6)
You Lu, MD (2) · Zhenyu Pan, PhD,MD (1)